Andrea Pantoja

Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis

Xpert MTB/RIF is a rapid test to diagnose tuberculosis (TB) and rifampicin-resistant TB. Cost and affordability will influence its uptake. We assessed the cost, globally and in 36 high-burden countries, of two strategies for diagnosing TB and multidrug-resistant (MDR)-TB: Xpert with follow-on diagnostics, and conventional diagnostics. Costs were compared with funding available for TB care and control, and donor investments in HIV prevention and care. Using Xpert to diagnose MDR-TB would cost US

Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002–11, and requirements to meet 2015 targets

70–90 million per year globally and be lower cost than conventional diagnostics globally and in all high-burden countries. Diagnosing TB in HIV-positive people using Xpert would also cost US

Financial resources required for tuberculosis control to achieve global targets set for 2015

90–101 million per year and be lower cost than conventional diagnostics globally and in 33 out of 36 high-burden countries. Testing everyone with TB signs and symptoms would cost US

Financiación de la lucha antituberculosa: papel de un sistema mundial de vigilancia financiera

434–468 million per year globally, much more than conventional diagnostics. However, in European countries, Brazil and South Africa, the cost would represent <10% of TB funding. Introducing Xpert to diagnose MDR-TB and to diagnose TB in HIV-positive people is warranted in many countries. Using it to test everyone with TB signs and symptoms is affordable in several middle-income countries, but financial viability in low-income countries requires large increases in TB funding and/or further price reductions. Use of Xpert for diagnosis of MDR-TB and TB in HIV-positive people is financially viable and justified globally http://ow.ly/mzPsv

Planning to improve global health: the next decade of tuberculosis control

BACKGROUND Progress in tuberculosis control worldwide, including achievement of 2015 global targets, requires adequate financing sustained for many years. WHO began yearly monitoring of tuberculosis funding in 2002. We used data reported to WHO to analyse tuberculosis funding from governments and international donors (in real terms, constant 2011 US

Financing tuberculosis control: the role of a global financial monitoring system

) and associated progress in tuberculosis control in low-income and middle-income countries between 2002 and 2011. We then assessed funding needed to 2015 and how this funding could be mobilised. METHODS We included low-income and middle-income countries that reported data about financing for tuberculosis to WHO and had at least three observations between 2002 and 2011. When data were missing for specific country-year combinations, we imputed the missing data. We aggregated country-specific results for eight country groups defined according to income level, political and economic profile, geography, and tuberculosis burden. We compared absolute changes in total funding with those in the total number of patients successfully treated and did cross-country comparisons of cost per successfully treated patient relative to gross domestic product. We estimated funding needs for tuberculosis care and control for all low-income and middle-income countries to 2015, and compared these needs with domestic funding that could be mobilised. FINDINGS Total funding grew from

Financing TB care and control

1·7 billion in 2002 to

Financial Resources Required for Tuberculosis Control to Achieve Global Targets Set for 2015/ Ressources Financieres Necessaires a la Lutte Antituberculeuse Pour Atteindre Les Cibles Mondiales Fixees Pour 2015/ Recursos Financieros Requeridos Para Controlar la Tuberculosis a Fin De Alcanzar Las Metas Mundiales Fijadas Para 2015

4·4 billion in 2011. It was mostly spent on diagnosis and treatment of drug-susceptible tuberculosis. 43 million patients were successfully treated, usually for

Recursos financieros requeridos para controlar la tuberculosis a fin de alcanzar las metas mundiales fijadas para 2015

100-500 per person in countries with high burdens of tuberculosis. Domestic funding rose from

Financing Tuberculosis Control: The Role of a Global Financial Monitoring system/Financement De la Lutte Antituberculeuse: Role D'un Systeme Mondial De Surveillance financiere/Financiacion De la Lucha Antituberculosa: Papel De Un Sistema Mundial De Vigilancia Financiera

1·5 billion to